Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.73 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | FLT4 | P35916 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396857 | 1.00 | NTRK1 (0.73) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL397140 | 0.88 | TLK2 (0.64) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL397139 | 0.88 | TLK2 (0.64) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL398830 | 0.85 | TLK2 (0.89) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL396901 | 0.85 | NTRK1 (1.00) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL396900 | 0.85 | NTRK1 (1.00) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL398831 | 0.85 | TLK2 (0.89) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL394527 | 0.83 | NTRK1 (0.58) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL394528 | 0.83 | NTRK1 (0.58) | NTRK1TLK2JAK3NTRK3AURKB | |
| SCHEMBL10091844 | 0.82 | NTRK1 (0.85) | NTRK1TLK2JAK3NTRK3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
| CN-1151187-A | Subtilisin 309 variants having decreased absorption and increased hydrolysis | PROCTER & GAMBLE (US) | 1997-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | NTRK1 226/4885TLK2 181/4885JAK3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.